Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Day One not changing endpoint for FIREFLY-1 trial, says JonesResearch » 15:27
03/24/23
03/24
15:27
03/24/23
15:27
DAWN

Day One Biopharmaceuticals

$15.70 /

-0.71 (-4.33%)

JonesResearch notes the…

JonesResearch notes the firm is getting a few investor questions around the recent change in the endpoint evaluation of FIREFLY-2 trial in first-line pediatric low grade glioma based on Day One Biopharmaceuticals' updated corporate deck, which indicates that the response rate will be evaluated by RANO-LGG versus the prior evaluation method of RANO-HGG. After having spoke with Day One's management, the analyst noted that they said that they will not change the endpoint evaluation for the upcoming data in Q2 and it will continue to be RANO-HGG. This means the ORR of 64% from the January update can be compared to the upcoming data readout, according to the analyst, who also notes that Day One is meeting with the FDA in Q2 for the pre-NDA meeting and there is a possibility that the FDA could ask for response rates based on RANO-LGG in addition. JonesResearch has a Buy rating and $40 price target on Day One shares, which are down 91c, or nearly 6%, to $15.51 in Friday afternoon trading.

ShowHide Related Items >><<
DAWN Day One Biopharmaceuticals
$15.70 /

-0.71 (-4.33%)

DAWN Day One Biopharmaceuticals
$15.70 /

-0.71 (-4.33%)

03/24/23 Oppenheimer
Day One FIREFLY-2 update brings two possible issues, says Oppenheimer
02/08/23 Capital One
Day One Biopharmaceuticals initiated with an Overweight at Capital One
02/02/23 Oppenheimer
Day One Biopharmaceuticals initiated with a Perform at Oppenheimer
01/09/23 H.C. Wainwright
Day One Biopharmaceuticals price target raised to $45 from $35 at H.C. Wainwright
DAWN Day One Biopharmaceuticals
$15.70 /

-0.71 (-4.33%)

  • 15
    Jun
DAWN Day One Biopharmaceuticals
$15.70 /

-0.71 (-4.33%)

Recommendations
Day One FIREFLY-2 update brings two possible issues, says Oppenheimer » 13:37
03/24/23
03/24
13:37
03/24/23
13:37
DAWN

Day One Biopharmaceuticals

$16.34 /

-0.07 (-0.43%)

Day One…

Day One Biopharmaceuticals on Monday revised its corporate deck, which included an update on FIREFLY-2's primary endpoint, which had changed from response assessment in neuro-oncology-high grade glioma to response assessment in neuro-Oncology criteria for low-grade gliomas, Oppenheimer analyst Matthew Biegler tells investors in a research note. The change was done to align with Novartis' (NVS) recently-approved dabra plus tram combination, which used RANO-LGG criteria, says the firm. Opco believes this admission creates two potential issues: the FDA might ask the company to change the endpoint in FIREFLY-1, potentially delaying accelerated approval, and tovorafenib's efficacy may now look a lot more like the dabra-tram combination, contends the analyst. Opco doesn't view either problem as deal-breakers for tovorafenib's ultimate approval, but says they could delay timelines and/or effect the drug's competitive posturing. It reiterates a Perform rating on Day One shares.

ShowHide Related Items >><<
DAWN Day One Biopharmaceuticals
$16.34 /

-0.07 (-0.43%)

DAWN Day One Biopharmaceuticals
$16.34 /

-0.07 (-0.43%)

02/08/23 Capital One
Day One Biopharmaceuticals initiated with an Overweight at Capital One
02/02/23 Oppenheimer
Day One Biopharmaceuticals initiated with a Perform at Oppenheimer
01/09/23 H.C. Wainwright
Day One Biopharmaceuticals price target raised to $45 from $35 at H.C. Wainwright
DAWN Day One Biopharmaceuticals
$16.34 /

-0.07 (-0.43%)

  • 15
    Jun
DAWN Day One Biopharmaceuticals
$16.34 /

-0.07 (-0.43%)

Over a month ago
Initiation
Day One Biopharmaceuticals initiated with an Overweight at Capital One » 08:52
02/08/23
02/08
08:52
02/08/23
08:52
DAWN

Day One Biopharmaceuticals

$20.89 /

-0.34 (-1.60%)

Capital One analyst…

Capital One analyst Naureen Quibria initiated coverage of Day One Biopharmaceuticals with an Overweight rating and $40 price target.

ShowHide Related Items >><<
DAWN Day One Biopharmaceuticals
$20.89 /

-0.34 (-1.60%)

DAWN Day One Biopharmaceuticals
$20.89 /

-0.34 (-1.60%)

02/02/23 Oppenheimer
Day One Biopharmaceuticals initiated with a Perform at Oppenheimer
01/09/23 H.C. Wainwright
Day One Biopharmaceuticals price target raised to $45 from $35 at H.C. Wainwright
01/08/23 Piper Sandler
Day One Biopharmaceuticals price target raised to $45 from $40 at Piper Sandler
12/15/22 H.C. Wainwright
Day One Biopharmaceuticals initiated with a Buy at H.C. Wainwright
DAWN Day One Biopharmaceuticals
$20.89 /

-0.34 (-1.60%)

  • 15
    Jun
DAWN Day One Biopharmaceuticals
$20.89 /

-0.34 (-1.60%)

DAWN Day One Biopharmaceuticals
$20.89 /

-0.34 (-1.60%)

On The Fly
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations » 09:35
02/03/23
02/03
09:35
02/03/23
09:35
IP

International Paper

$41.53 /

+0.7 (+1.71%)

, BA

Boeing

$209.24 /

-5.265 (-2.45%)

, LSPD

Lightspeed

$17.55 /

-1.175 (-6.28%)

, SYNA

Synaptics

$139.79 /

+7.25 (+5.47%)

, JWN

Nordstrom

$21.14 /

+1.155 (+5.78%)

, CAH

Cardinal Health

$76.33 /

+0.62 (+0.82%)

, META

Meta Platforms

$188.78 /

+35.675 (+23.30%)

, F

Ford

$14.34 /

+0.535 (+3.88%)

, DAWN

Day One Biopharmaceuticals

$21.67 /

+0.165 (+0.77%)

, HLF

Herbalife Nutrition

$18.25 /

-0.325 (-1.75%)

, AGIO

Agios Pharmaceuticals

$30.16 /

+0.74 (+2.52%)

, NBIX

Neurocrine

$107.96 /

-2.045 (-1.86%)

, FUL

H.B. Fuller

$73.22 /

+2.91 (+4.14%)

, ENPH

Enphase Energy

$227.87 /

+0.84 (+0.37%)

, PRVA

Privia Health

$27.62 /

+0.05 (+0.18%)

Institutional investors…

ShowHide Related Items >><<
SYNA Synaptics
$139.79 /

+7.25 (+5.47%)

PRVA Privia Health
$27.62 /

+0.05 (+0.18%)

NBIX Neurocrine
$107.96 /

-2.045 (-1.86%)

META Meta Platforms
$188.78 /

+35.675 (+23.30%)

LSPD Lightspeed
$17.55 /

-1.175 (-6.28%)

JWN Nordstrom
$21.14 /

+1.155 (+5.78%)

IP International Paper
$41.53 /

+0.7 (+1.71%)

HLF Herbalife Nutrition
$18.25 /

-0.325 (-1.75%)

FUL H.B. Fuller
$73.22 /

+2.91 (+4.14%)

F Ford
$14.34 /

+0.535 (+3.88%)

ENPH Enphase Energy
$227.87 /

+0.84 (+0.37%)

DAWN Day One Biopharmaceuticals
$21.67 /

+0.165 (+0.77%)

CAH Cardinal Health
$76.33 /

+0.62 (+0.82%)

BA Boeing
$209.24 /

-5.265 (-2.45%)

AGIO Agios Pharmaceuticals
$30.16 /

+0.74 (+2.52%)

IP International Paper
$41.53 /

+0.7 (+1.71%)

02/03/23 UBS
International Paper upgraded to Neutral from Sell at UBS
02/03/23 UBS
International Paper upgraded to Neutral from Sell at UBS
02/02/23 Argus
International Paper price target raised to $50 from $43 at Argus
02/01/23 Truist
International Paper price target raised to $38 from $30 at Truist
BA Boeing
$209.24 /

-5.265 (-2.45%)

02/03/23 RBC Capital
Boeing downgraded to Sector Perform from Outperform at RBC Capital
01/30/23 Jefferies
Boeing price target raised to $250 from $240 at Jefferies
01/26/23 Morgan Stanley
Boeing remains a 'show me story,' says Morgan Stanley
01/12/23 Credit Suisse
Credit Suisse upgrades Boeing to Neutral, raises price target to $200
LSPD Lightspeed
$17.55 /

-1.175 (-6.28%)

02/03/23 Credit Suisse
Lightspeed downgraded to Neutral from Outperform at Credit Suisse
02/02/23 CIBC
Lightspeed downgraded to Neutral from Outperformer at CIBC
01/25/23 BofA
Lightspeed initiated with a Neutral at BofA
01/25/23 BofA
Lightspeed initiated with a Neutral at BofA
SYNA Synaptics
$139.79 /

+7.25 (+5.47%)

02/03/23 Craig-Hallum
Synaptics price target raised to $150 from $120 at Craig-Hallum
02/03/23 Susquehanna
Synaptics price target raised to $145 from $115
02/03/23 Oppenheimer
Synaptics downgraded to Perform from Outperform at Oppenheimer
02/03/23 TD Cowen
Synaptics price target raised to $150 from $100 at Cowen
JWN Nordstrom
$21.14 /

+1.155 (+5.78%)

02/03/23 William Blair
Nordstrom performance 'begs for an activist role,' says William Blair
02/03/23 Gordon Haskett
Nordstrom upgraded to Hold from Reduce at Gordon Haskett
01/30/23 Goldman Sachs
Nordstrom initiated with a Neutral at Goldman Sachs
01/20/23 Deutsche Bank
Nordstrom price target lowered to $17 from $21 at Deutsche Bank
CAH Cardinal Health
$76.33 /

+0.62 (+0.82%)

02/03/23 Baird
Baird upgrades Cardinal Health, sees 'value trap label' ending
02/03/23 Baird
Cardinal Health upgraded to Outperform from Neutral at Baird
01/31/23 UBS
Cardinal Health price target raised to $91 from $78 at UBS
11/22/22 Credit Suisse
Cardinal Health price target raised to $79 from $64 at Credit Suisse
META Meta Platforms
$188.78 /

+35.675 (+23.30%)

02/03/23 DA Davidson
Amazon.com price target raised to $134 from $114 at DA Davidson
02/03/23 HSBC
Meta Platforms downgraded to Reduce from Hold at HSBC
02/03/23 DZ Bank
Meta Platforms upgraded to Hold from Sell at DZ Bank
02/02/23 Deutsche Bank
Meta Platforms price target raised to $200 from $125 at Deutsche Bank
F Ford
$14.34 /

+0.535 (+3.88%)

02/03/23 Benchmark
Ford price target lowered to $19 from $21 at Benchmark
02/03/23 Deutsche Bank
Deutsche downgrades Ford to Sell on 'meaningful' earnings risk
02/03/23 Deutsche Bank
Ford downgraded to Sell from Hold at Deutsche Bank
01/25/23 JPMorgan
Ford price target lowered to $15 from $16 at JPMorgan
DAWN Day One Biopharmaceuticals
$21.67 /

+0.165 (+0.77%)

02/02/23 Oppenheimer
Day One Biopharmaceuticals initiated with a Perform at Oppenheimer
01/09/23 H.C. Wainwright
Day One Biopharmaceuticals price target raised to $45 from $35 at H.C. Wainwright
01/08/23 Piper Sandler
Day One Biopharmaceuticals price target raised to $45 from $40 at Piper Sandler
12/15/22 H.C. Wainwright
Day One Biopharmaceuticals initiated with a Buy at H.C. Wainwright
HLF Herbalife Nutrition
$18.25 /

-0.325 (-1.75%)

02/03/23 BofA
Herbalife Nutrition initiated with an Underperform at BofA
11/01/22 B. Riley
Herbalife Nutrition price target lowered to $31 from $38 at B. Riley
11/01/22 Citi
Herbalife Nutrition price target lowered to $26 from $30 at Citi
10/05/22 Citi
Herbalife Nutrition price target lowered to $30 from $36 at Citi
AGIO Agios Pharmaceuticals
$30.16 /

+0.74 (+2.52%)

02/03/23 Piper Sandler
Agios Pharmaceuticals initiated with an Overweight at Piper Sandler
11/17/22 Goldman Sachs
Agios Pharmaceuticals upgraded to Neutral from Sell at Goldman Sachs
07/27/22 SVB Securities
Agios Pharmaceuticals upgraded to Outperform from Market Perform at SVB Securities
02/25/22 RBC Capital
Agios Pharmaceuticals price target raised to $67 from $61 at RBC Capital
NBIX Neurocrine
$107.96 /

-2.045 (-1.86%)

02/03/23 Morgan Stanley
Neurocrine upgraded to Overweight from Equal Weight at Morgan Stanley
12/13/22 RBC Capital
Neurocrine CAH data appears pushed back, says RBC Capital
11/14/22 Evercore ISI
Neurocrine downgraded to In Line from Outperform at Evercore ISI
11/02/22 BMO Capital
Neurocrine price target raised to $101 from $78 at BMO Capital
FUL H.B. Fuller
$73.22 /

+2.91 (+4.14%)

02/03/23 Citi
H.B. Fuller upgraded to Buy from Neutral at Citi
01/23/23 Citi
H.B. Fuller price target raised to $72 from $65 at Citi
01/20/23 Deutsche Bank
H.B. Fuller price target raised to $78 from $72 at Deutsche Bank
01/20/23 Baird
H.B. Fuller price target lowered to $80 from $85 at Baird
ENPH Enphase Energy
$227.87 /

+0.84 (+0.37%)

02/03/23 Truist
Enphase Energy price target lowered to $285 from $325 at Truist
02/03/23 Janney Montgomery Scott
Enphase Energy initiated with a Neutral at Janney Montgomery Scott
02/01/23 Barclays
SolarEdge price target lowered to $392 from $396 at Barclays
02/01/23 Barclays
Enphase Energy price target lowered to $251 from $311 at Barclays
PRVA Privia Health
$27.62 /

+0.05 (+0.18%)

02/03/23 Goldman Sachs
Privia Health initiated with a Buy at Goldman Sachs
01/17/23 Piper Sandler
Piper Sandler would be a buyer of Privia Health following CMS data
01/09/23 BTIG
Privia Health price target lowered to $40 from $45 at BTIG
12/08/22 Stifel
Privia Health initiated with a Buy at Stifel
SYNA Synaptics
$139.79 /

+7.25 (+5.47%)

PRVA Privia Health
$27.62 /

+0.05 (+0.18%)

NBIX Neurocrine
$107.96 /

-2.045 (-1.86%)

META Meta Platforms
$188.78 /

+35.675 (+23.30%)

LSPD Lightspeed
$17.55 /

-1.175 (-6.28%)

JWN Nordstrom
$21.14 /

+1.155 (+5.78%)

IP International Paper
$41.53 /

+0.7 (+1.71%)

HLF Herbalife Nutrition
$18.25 /

-0.325 (-1.75%)

FUL H.B. Fuller
$73.22 /

+2.91 (+4.14%)

F Ford
$14.34 /

+0.535 (+3.88%)

ENPH Enphase Energy
$227.87 /

+0.84 (+0.37%)

DAWN Day One Biopharmaceuticals
$21.67 /

+0.165 (+0.77%)

CAH Cardinal Health
$76.33 /

+0.62 (+0.82%)

BA Boeing
$209.24 /

-5.265 (-2.45%)

AGIO Agios Pharmaceuticals
$30.16 /

+0.74 (+2.52%)

  • 17
    Nov
  • 15
    Jun
META Meta Platforms
$188.78 /

+35.675 (+23.30%)

JWN Nordstrom
$21.14 /

+1.155 (+5.78%)

F Ford
$14.34 /

+0.535 (+3.88%)

CAH Cardinal Health
$76.33 /

+0.62 (+0.82%)

BA Boeing
$209.24 /

-5.265 (-2.45%)

PRVA Privia Health
$27.62 /

+0.05 (+0.18%)

NBIX Neurocrine
$107.96 /

-2.045 (-1.86%)

META Meta Platforms
$188.78 /

+35.675 (+23.30%)

LSPD Lightspeed
$17.55 /

-1.175 (-6.28%)

JWN Nordstrom
$21.14 /

+1.155 (+5.78%)

IP International Paper
$41.53 /

+0.7 (+1.71%)

HLF Herbalife Nutrition
$18.25 /

-0.325 (-1.75%)

FUL H.B. Fuller
$73.22 /

+2.91 (+4.14%)

F Ford
$14.34 /

+0.535 (+3.88%)

ENPH Enphase Energy
$227.87 /

+0.84 (+0.37%)

DAWN Day One Biopharmaceuticals
$21.67 /

+0.165 (+0.77%)

CAH Cardinal Health
$76.33 /

+0.62 (+0.82%)

BA Boeing
$209.24 /

-5.265 (-2.45%)

AGIO Agios Pharmaceuticals
$30.16 /

+0.74 (+2.52%)

META Meta Platforms
$188.78 /

+35.675 (+23.30%)

LSPD Lightspeed
$17.55 /

-1.175 (-6.28%)

JWN Nordstrom
$21.14 /

+1.155 (+5.78%)

IP International Paper
$41.53 /

+0.7 (+1.71%)

HLF Herbalife Nutrition
$18.25 /

-0.325 (-1.75%)

F Ford
$14.34 /

+0.535 (+3.88%)

ENPH Enphase Energy
$227.87 /

+0.84 (+0.37%)

DAWN Day One Biopharmaceuticals
$21.67 /

+0.165 (+0.77%)

CAH Cardinal Health
$76.33 /

+0.62 (+0.82%)

BA Boeing
$209.24 /

-5.265 (-2.45%)

Initiation
Day One Biopharmaceuticals initiated with a Perform at Oppenheimer » 16:08
02/02/23
02/02
16:08
02/02/23
16:08
DAWN

Day One Biopharmaceuticals

$21.67 /

+0.165 (+0.77%)

Oppenheimer analyst…

Oppenheimer analyst Matthew Biegler initiated coverage of Day One Biopharmaceuticals with a Perform rating and no price target. While stating "there's a lot to like about this story," including management and data to date, but "lost in the hype, in our view, lie real risks," the analyst tells investors in a research note. The two big "ifs" Oppenheimer highlights are whether or not tovorafenib will get accelerated approval based on its efficacy and safety profile and also the true market opportunity for the drug, which the firm calls "harder to estimate."

ShowHide Related Items >><<
DAWN Day One Biopharmaceuticals
$21.67 /

+0.165 (+0.77%)

DAWN Day One Biopharmaceuticals
$21.67 /

+0.165 (+0.77%)

01/09/23 H.C. Wainwright
Day One Biopharmaceuticals price target raised to $45 from $35 at H.C. Wainwright
01/08/23 Piper Sandler
Day One Biopharmaceuticals price target raised to $45 from $40 at Piper Sandler
12/15/22 H.C. Wainwright
Day One Biopharmaceuticals initiated with a Buy at H.C. Wainwright
12/14/22 Needham
Day One Biopharmaceuticals initiated with a Buy at Needham
DAWN Day One Biopharmaceuticals
$21.67 /

+0.165 (+0.77%)

  • 15
    Jun
DAWN Day One Biopharmaceuticals
$21.67 /

+0.165 (+0.77%)

DAWN Day One Biopharmaceuticals
$21.67 /

+0.165 (+0.77%)

Recommendations
Day One Biopharmaceuticals price target raised to $45 from $35 at H.C. Wainwright » 06:18
01/09/23
01/09
06:18
01/09/23
06:18
DAWN

Day One Biopharmaceuticals

$21.35 /

+0.2 (+0.95%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Andres Maldonado raised the firm's price target on Day One Biopharmaceuticals to $45 from $35 and keeps a Buy rating on the shares. The analyst says tovorafenib continues to maintain an approvable profile.

ShowHide Related Items >><<
DAWN Day One Biopharmaceuticals
$21.35 /

+0.2 (+0.95%)

DAWN Day One Biopharmaceuticals
$21.35 /

+0.2 (+0.95%)

01/08/23 Piper Sandler
Day One Biopharmaceuticals price target raised to $45 from $40 at Piper Sandler
12/15/22 H.C. Wainwright
Day One Biopharmaceuticals initiated with a Buy at H.C. Wainwright
12/14/22 Needham
Day One Biopharmaceuticals initiated with a Buy at Needham
12/14/22 Needham
Day One Biopharmaceuticals initiated with a Buy at Needham
DAWN Day One Biopharmaceuticals
$21.35 /

+0.2 (+0.95%)

  • 15
    Jun
DAWN Day One Biopharmaceuticals
$21.35 /

+0.2 (+0.95%)

DAWN Day One Biopharmaceuticals
$21.35 /

+0.2 (+0.95%)

Recommendations
Day One Biopharmaceuticals price target raised to $45 from $40 at Piper Sandler » 19:32
01/08/23
01/08
19:32
01/08/23
19:32
DAWN

Day One Biopharmaceuticals

$21.35 /

+0.2 (+0.95%)

Piper Sandler analyst…

Piper Sandler analyst Joseph Catanzaro raised the firm's price target on Day One Biopharmaceuticals to $45 from $40 and keeps an Overweight rating on the shares. The analyst notes that the company reported positive topline data from tovorafenib's pivotal Phase II FIREFLY-1 study in recurrent/progressive pediatric low-grade glioma, with all data points clearly beating expectations. One more data cut is expected to provide additional follow-up and will be used to support an NDA submission and full presentation at a medical meeting, both in the first half of 2023, Catanzaro adds. He sees these data as a significant derisking event and supportive of what he believes is a sizable orphan oncology opportunity.

ShowHide Related Items >><<
DAWN Day One Biopharmaceuticals
$21.35 /

+0.2 (+0.95%)

DAWN Day One Biopharmaceuticals
$21.35 /

+0.2 (+0.95%)

12/15/22 H.C. Wainwright
Day One Biopharmaceuticals initiated with a Buy at H.C. Wainwright
12/14/22 Needham
Day One Biopharmaceuticals initiated with a Buy at Needham
12/14/22 Needham
Day One Biopharmaceuticals initiated with a Buy at Needham
12/05/22 Goldman Sachs
Day One Biopharmaceuticals initiated with a Buy at Goldman Sachs
DAWN Day One Biopharmaceuticals
$21.35 /

+0.2 (+0.95%)

  • 15
    Jun
DAWN Day One Biopharmaceuticals
$21.35 /

+0.2 (+0.95%)

DAWN Day One Biopharmaceuticals
$21.35 /

+0.2 (+0.95%)

Hot Stocks
Day One announces top line data from pivotal Phase 2 FIREFLY-1 trial » 17:26
01/08/23
01/08
17:26
01/08/23
17:26
DAWN

Day One Biopharmaceuticals

$21.35 /

+0.2 (+0.95%)

Day One…

Day One Biopharmaceuticals announced positive top line results from the ongoing, open-label, pivotal Phase 2 FIREFLY-1 trial evaluating the investigational agent, tovorafenib, as a monotherapy in recurrent or progressive pediatric low-grade glioma. Pediatric low-grade glioma is the most common brain tumor diagnosed in children and for which there is no standard of care, and for which there are no approved therapies for the majority of patients. Additional data will be submitted for presentation at an upcoming medical meeting in the second quarter of 2023. The primary endpoint of the FIREFLY-1 trial is overall response rate by Response Assessment for Neuro-Oncology criteria as assessed by blinded independent central review. Top line results as of September 28, 2022 include: among 69 RANO-evaluable patients -- 64% ORR and 91% clinical benefit rate; 4% confirmed complete responses; 59% partial responses; 28% patients with stable disease; 86% of patients had a BRAF fusion alteration, for which there are no approved systemic therapies, while the remaining 14% had a BRAF mutation. Safety data, based on 77 treated patients, indicated monotherapy tovorafenib to be generally well-tolerated. Among a total of 77 treated patients: Participants were heavily pretreated, with a median of three prior lines of systemic therapy; The median duration of tovorafenib treatment was 8.4 months, with 77% of patients on treatment at the time of the data cutoff; Nearly 60% of patients had already received at least one prior MAPK inhibitor prior to study participation. In addition to FIREFLY-1, Day One is expanding the development of tovorafenib as a front-line therapy for patients newly diagnosed with pLGG. The global, Phase 3, registrational FIREFLY-2/LOGGIC clinical trial is evaluating once-weekly monotherapy tovorafenib in newly-diagnosed patients with pLGG harboring a known activating RAF alteration.

ShowHide Related Items >><<
DAWN Day One Biopharmaceuticals
$21.35 /

+0.2 (+0.95%)

DAWN Day One Biopharmaceuticals
$21.35 /

+0.2 (+0.95%)

12/15/22 H.C. Wainwright
Day One Biopharmaceuticals initiated with a Buy at H.C. Wainwright
12/14/22 Needham
Day One Biopharmaceuticals initiated with a Buy at Needham
12/14/22 Needham
Day One Biopharmaceuticals initiated with a Buy at Needham
12/05/22 Goldman Sachs
Day One Biopharmaceuticals initiated with a Buy at Goldman Sachs
DAWN Day One Biopharmaceuticals
$21.35 /

+0.2 (+0.95%)

  • 15
    Jun
DAWN Day One Biopharmaceuticals
$21.35 /

+0.2 (+0.95%)

DAWN Day One Biopharmaceuticals
$21.35 /

+0.2 (+0.95%)

Over a quarter ago
Initiation
Day One Biopharmaceuticals initiated with a Buy at H.C. Wainwright » 06:07
12/15/22
12/15
06:07
12/15/22
06:07
DAWN

Day One Biopharmaceuticals

$21.65 /

+1.535 (+7.63%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Andres Maldonado initiated coverage of Day One Biopharmaceuticals with a Buy rating and $35 price target. The company continues to garner an impressive clinical profile in BRAF-associated relapsed pediatric low-grade glioma where there are no approved therapies or standard of care, Maldonado tells investors in a research note. The analyst is positive ahead of FIREFLY-1's topline data in Q1 of 2023.

ShowHide Related Items >><<
DAWN Day One Biopharmaceuticals
$21.65 /

+1.535 (+7.63%)

DAWN Day One Biopharmaceuticals
$21.65 /

+1.535 (+7.63%)

12/14/22 Needham
Day One Biopharmaceuticals initiated with a Buy at Needham
12/14/22 Needham
Day One Biopharmaceuticals initiated with a Buy at Needham
12/05/22 Goldman Sachs
Day One Biopharmaceuticals initiated with a Buy at Goldman Sachs
12/01/22 BofA
Day One Biopharmaceuticals initiated with a Buy, $34 price target at BofA
DAWN Day One Biopharmaceuticals
$21.65 /

+1.535 (+7.63%)

  • 15
    Jun
DAWN Day One Biopharmaceuticals
$21.65 /

+1.535 (+7.63%)

DAWN Day One Biopharmaceuticals
$21.65 /

+1.535 (+7.63%)

Initiation
Day One Biopharmaceuticals initiated with a Buy at Needham » 07:21
12/14/22
12/14
07:21
12/14/22
07:21
DAWN

Day One Biopharmaceuticals

$20.12 /

+0.16 (+0.80%)

Needham analyst Ami Fadia…

Needham analyst Ami Fadia initiated coverage of Day One Biopharmaceuticals with a Buy rating and $40 price target. The analyst, who added shares to the firm's Conviction List, tells investors in a research note that Tovorafenib could become a best-in-class RAF inhibitor for pediatric low-grade glioma, and thinks it will be the only approved, targeted therapy for the 85% of the BRAF population with no options other than chemo.

ShowHide Related Items >><<
DAWN Day One Biopharmaceuticals
$20.12 /

+0.16 (+0.80%)

DAWN Day One Biopharmaceuticals
$20.12 /

+0.16 (+0.80%)

12/14/22 Needham
Day One Biopharmaceuticals initiated with a Buy at Needham
12/05/22 Goldman Sachs
Day One Biopharmaceuticals initiated with a Buy at Goldman Sachs
12/01/22 BofA
Day One Biopharmaceuticals initiated with a Buy, $34 price target at BofA
12/01/22 BofA
Day One Biopharmaceuticals initiated with a Buy at BofA
DAWN Day One Biopharmaceuticals
$20.12 /

+0.16 (+0.80%)

  • 15
    Jun
DAWN Day One Biopharmaceuticals
$20.12 /

+0.16 (+0.80%)

DAWN Day One Biopharmaceuticals
$20.12 /

+0.16 (+0.80%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.